PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsEtoricoxib
Etoricoxib
Etoricoxib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against prostaglandin G/H synthase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M01: Antiinflammatory and antirheumatic products
— M01A: Antiinflammatory and antirheumatic products, non-steroids
— M01AH: Coxibs
— M01AH05: Etoricoxib
HCPCS
No data
Clinical
Clinical Trials
122 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149—G89.18—212—5
OsteoarthritisD010003EFO_0002506M15-M19—3—1—4
PainD010146EFO_0003843R52—1—2—3
Knee osteoarthritisD020370EFO_0004616M17—2—1—3
Sprains and strainsD013180—————2—2
NeuralgiaD009437EFO_0009430————1—1
Postherpetic neuralgiaD051474—————1—1
TendinopathyD052256EFO_1001434M77.9———1—1
HyperalgesiaD006930—————1—1
AppendicitisD001064EFO_0007149K37———1—1
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hip osteoarthritisD015207EFO_1000786M16—11——2
Low back painD017116—M54.5——1——1
Back painD001416—M54——1——1
HysterectomyD007044EFO_0003881———1——1
OvariectomyD010052————1——1
SalpingectomyD058994————1——1
Surgical blood lossD016063————1——1
Replacement arthroplasty hipD019644————1——1
Rheumatic diseasesD012216—M79.0——1——1
BursitisD002062EFO_1000941M71.9——1——1
Show 3 more
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEtoricoxib
INNetoricoxib
Description
Etoricoxib is a member of the class of bipyridines that is 2,3'-bipyridine which is substituted at the 3, 5, and 6' positions by 4-(methylsulfonyl)phenyl, chlorine, and methyl groups, respectively. It has a role as a cyclooxygenase 2 inhibitor and a non-steroidal anti-inflammatory drug. It is a sulfone, a member of bipyridines and an organochlorine compound.
Classification
Small molecule
Drug classcyclooxygenase-2 inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
Identifiers
PDB—
CAS-ID202409-33-4
RxCUI—
ChEMBL IDCHEMBL416146
ChEBI ID6339
PubChem CID123619
DrugBankDB01628
UNII IDWRX4NFY03R (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Etoricoxib – Organon
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,222 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,378 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use